2-168968498-A-C
Position:
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM2PP5_Very_Strong
The NM_003742.4(ABCB11):c.2012-8T>G variant causes a splice region, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000827 in 1,607,848 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000046 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000087 ( 0 hom. )
Consequence
ABCB11
NM_003742.4 splice_region, intron
NM_003742.4 splice_region, intron
Scores
2
Splicing: ADA: 0.9881
1
Clinical Significance
Conservation
PhyloP100: 2.19
Genes affected
ABCB11 (HGNC:42): (ATP binding cassette subfamily B member 11) The membrane-associated protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MDR/TAP subfamily. Members of the MDR/TAP subfamily are involved in multidrug resistance. The protein encoded by this gene is the major canalicular bile salt export pump in man. Mutations in this gene cause a form of progressive familial intrahepatic cholestases which are a group of inherited disorders with severe cholestatic liver disease from early infancy. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 2-168968498-A-C is Pathogenic according to our data. Variant chr2-168968498-A-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 284637.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ABCB11 | NM_003742.4 | c.2012-8T>G | splice_region_variant, intron_variant | ENST00000650372.1 | NP_003733.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ABCB11 | ENST00000650372.1 | c.2012-8T>G | splice_region_variant, intron_variant | NM_003742.4 | ENSP00000497931.1 | |||||
ABCB11 | ENST00000649448.1 | c.329-8T>G | splice_region_variant, intron_variant | ENSP00000497165.1 | ||||||
ABCB11 | ENST00000439188.1 | n.*482-8T>G | splice_region_variant, intron_variant | 2 | ENSP00000416058.1 |
Frequencies
GnomAD3 genomes AF: 0.0000461 AC: 7AN: 151946Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
7
AN:
151946
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000245 AC: 6AN: 244560Hom.: 0 AF XY: 0.0000377 AC XY: 5AN XY: 132542
GnomAD3 exomes
AF:
AC:
6
AN:
244560
Hom.:
AF XY:
AC XY:
5
AN XY:
132542
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000865 AC: 126AN: 1455902Hom.: 0 Cov.: 30 AF XY: 0.0000857 AC XY: 62AN XY: 723702
GnomAD4 exome
AF:
AC:
126
AN:
1455902
Hom.:
Cov.:
30
AF XY:
AC XY:
62
AN XY:
723702
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000461 AC: 7AN: 151946Hom.: 0 Cov.: 33 AF XY: 0.0000539 AC XY: 4AN XY: 74204
GnomAD4 genome
AF:
AC:
7
AN:
151946
Hom.:
Cov.:
33
AF XY:
AC XY:
4
AN XY:
74204
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 13, 2023 | Non-canonical splice site variant demonstrated to result in loss of function (Strautnieks et al., 2008); This variant is associated with the following publications: (PMID: 16871584, 32581362, 35894240, 24402531, 20583290, 24231640, 18395098) - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Feb 01, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 21, 2023 | This sequence change falls in intron 16 of the ABCB11 gene. It does not directly change the encoded amino acid sequence of the ABCB11 protein. This variant is present in population databases (rs769910565, gnomAD 0.006%). This variant has been observed in individuals with ABCB11-related conditions (PMID: 18395098). ClinVar contains an entry for this variant (Variation ID: 284637). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Progressive familial intrahepatic cholestasis type 2 Pathogenic:2
Likely pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Jan 22, 2021 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Oct 23, 2018 | The ABCB11 c.2012-8T>G variant has been identified in a compound heterozygous state in at least six probands and in a heterozygous state in one proband in whom a second variant was not identified, all with familial intrahepatic cholestasis (Knisely et al. 2006; Siebold et al. 2010; Strautnieks et al. 2008; Grammatikopoulos et al. 2015). The c.2012-8T>G variant was absent from 500 control individuals and is reported at a frequency of 0.000056 in the European (non-Finnish) population of the Genome Aggregation Database. Based on the evidence, the c.2012-8T>G variant is classified as likely pathogenic for familial intrahepatic cholestasis. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
ABCB11-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 04, 2023 | The ABCB11 c.2012-8T>G variant is predicted to interfere with splicing. This variant was previously reported in the compound heterozygous state in individuals who presented with familial intrahepatic cholestasis (Knisely et al. 2006. PubMed ID: 16871584, reported as IVS16-8T>G; Siebold et al. 2010. PubMed ID: 20583290; Strautnieks et al. 2008. PubMed ID: 18395098). In vitro analysis from one study indicated that this variant led to skipping of exon 17 and a resulting frameshift with premature protein termination (Knisely et al. 2006. PubMed ID: 16871584). This variant is reported in 0.0056% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/2-169825008-A-C) and is interpreted as pathogenic/likely pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/284637/). This variant is interpreted as pathogenic. - |
Cholestasis, intrahepatic, of pregnancy, 3 Pathogenic:1
Likely pathogenic, no assertion criteria provided | research | NIHR Bioresource Rare Diseases, University of Cambridge | - | - - |
Benign recurrent intrahepatic cholestasis type 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 12, 2024 | - - |
Benign recurrent intrahepatic cholestasis type 2;C3489789:Progressive familial intrahepatic cholestasis type 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Progressive familial intrahepatic cholestasis Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 11, 2023 | Variant summary: ABCB11 c.2012-8T>G alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Several computational tools predict a significant impact on normal splicing: Three predict the variant creates a 3' cryptic acceptor site. One predict the variant no significant impact on splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 2.5e-05 in 244560 control chromosomes. c.2012-8T>G has been reported in the literature at a compound heterozygous state along with difference pathogenic variants in multiple individuals affected with Familial Intrahepatic Cholestasis (examples, Knisely_2006, Strautnieks_2008). These data indicate that the variant is very likely to be associated with disease. One publication reports experimental evidence evaluating an impact on splicing, however, detailed information of such results are not available for an independent evaluation (Strautnieks_2008). The following publications have been ascertained in the context of this evaluation (PMID: 16871584, 18395098). Seven submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AL_spliceai
Position offset: -8
Find out detailed SpliceAI scores and Pangolin per-transcript scores at